Poland · Delayed Price · Currency is PLN Biogened Statistics
Total Valuation
Biogened has a market cap or net worth of PLN 48.88 million. The enterprise value is 67.63 million.
| Market Cap | 48.88M |
| Enterprise Value | 67.63M |
Important Dates
The last earnings date was Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | Sep 10, 2026 |
Share Statistics
Biogened has 2.46 million shares outstanding.
| Current Share Class | 2.46M |
| Shares Outstanding | 2.46M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 1.03% |
| Float | 144,714 |
Valuation Ratios
The trailing PE ratio is 9.54.
| PE Ratio | 9.54 |
| Forward PE | n/a |
| PS Ratio | 0.44 |
| PB Ratio | 1.02 |
| P/TBV Ratio | 1.06 |
| P/FCF Ratio | 6.60 |
| P/OCF Ratio | 3.29 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.22, with an EV/FCF ratio of 9.14.
| EV / Earnings | 13.19 |
| EV / Sales | 0.61 |
| EV / EBITDA | 5.22 |
| EV / EBIT | 8.35 |
| EV / FCF | 9.14 |
Financial Position
The company has a current ratio of 2.50, with a Debt / Equity ratio of 0.61.
| Current Ratio | 2.50 |
| Quick Ratio | 1.32 |
| Debt / Equity | 0.61 |
| Debt / EBITDA | 2.24 |
| Debt / FCF | 3.92 |
| Interest Coverage | 4.17 |
Financial Efficiency
Return on equity (ROE) is 11.20% and return on invested capital (ROIC) is 9.77%.
| Return on Equity (ROE) | 11.20% |
| Return on Assets (ROA) | 5.31% |
| Return on Invested Capital (ROIC) | 9.77% |
| Return on Capital Employed (ROCE) | 10.91% |
| Weighted Average Cost of Capital (WACC) | 4.64% |
| Revenue Per Employee | 591,981 |
| Profits Per Employee | 27,558 |
| Employee Count | 186 |
| Asset Turnover | 1.15 |
| Inventory Turnover | 1.64 |
Taxes
In the past 12 months, Biogened has paid 1.14 million in taxes.
| Income Tax | 1.14M |
| Effective Tax Rate | 18.16% |
Stock Price Statistics
The stock price has decreased by -22.76% in the last 52 weeks. The beta is -0.02, so Biogened's price volatility has been lower than the market average.
| Beta (5Y) | -0.02 |
| 52-Week Price Change | -22.76% |
| 50-Day Moving Average | 19.09 |
| 200-Day Moving Average | 20.93 |
| Relative Strength Index (RSI) | 53.13 |
| Average Volume (20 Days) | 88 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Biogened had revenue of PLN 110.11 million and earned 5.13 million in profits. Earnings per share was 2.09.
| Revenue | 110.11M |
| Gross Profit | 73.06M |
| Operating Income | 8.10M |
| Pretax Income | 6.26M |
| Net Income | 5.13M |
| EBITDA | 12.97M |
| EBIT | 8.10M |
| Earnings Per Share (EPS) | 2.09 |
Balance Sheet
The company has 10.29 million in cash and 29.04 million in debt, with a net cash position of -18.75 million or -7.63 per share.
| Cash & Cash Equivalents | 10.29M |
| Total Debt | 29.04M |
| Net Cash | -18.75M |
| Net Cash Per Share | -7.63 |
| Equity (Book Value) | 47.71M |
| Book Value Per Share | 19.42 |
| Working Capital | 34.34M |
Cash Flow
In the last 12 months, operating cash flow was 14.84 million and capital expenditures -7.44 million, giving a free cash flow of 7.40 million.
| Operating Cash Flow | 14.84M |
| Capital Expenditures | -7.44M |
| Depreciation & Amortization | 4.87M |
| Net Borrowing | 717,903 |
| Free Cash Flow | 7.40M |
| FCF Per Share | 3.01 |
Margins
Gross margin is 66.35%, with operating and profit margins of 7.36% and 4.66%.
| Gross Margin | 66.35% |
| Operating Margin | 7.36% |
| Pretax Margin | 5.69% |
| Profit Margin | 4.66% |
| EBITDA Margin | 11.78% |
| EBIT Margin | 7.36% |
| FCF Margin | 6.72% |
Dividends & Yields
This stock pays an annual dividend of 0.50, which amounts to a dividend yield of 2.63%.
| Dividend Per Share | 0.50 |
| Dividend Yield | 2.63% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 23.96% |
| Buyback Yield | n/a |
| Shareholder Yield | 2.63% |
| Earnings Yield | 10.49% |
| FCF Yield | 15.14% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Biogened has an Altman Z-Score of 2.54 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.54 |
| Piotroski F-Score | 5 |